VP-102 Emerging Drug Insight and Market Forecast - 2032

“VP-102 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about VP-102 for Common Warts in the seven major markets. A detailed picture of the VP-102 for Common Warts in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the VP-102 for Common Warts. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VP-102 market forecast, analysis for Common Warts in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Common Warts.

Drug Summary

VP-102 is a controlled, shelf-stable drug-device combination product with a topical solution that contains cantharidin (0.7% w/v) manufactured according to current good manufacturing practices, delivered via a single-use applicator that allows for precise topical dosing and targeted administration.

The mechanism of action of VP-102 is unknown. However, the pharmacodynamic action of the active ingredient in VP-102 (cantharidin) is a vesicant. VP-102 is currently under the US FDA review and could potentially be the first product approved by the FDA to treat molluscum contagiosum (molluscum) - a common, highly contagious skin disease that affects an estimated 6 million people in the United States, primarily children.

Verrica has announced positive top-line results from its COVE-1 Phase II open-label clinical study of VP-102 to treat common warts.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VP-102 description, mechanism of action, dosage and administration, research and development activities in Common Warts.
• Elaborated details on VP-102 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VP-102 research and development activity in Common Warts in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VP-102.
• The report contains forecasted sales of VP-102 for Common Warts till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Common Warts.
• The report also features the SWOT analysis with analyst views for VP-102 in Common Warts.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VP-102 Analytical Perspective

In-depth VP-102 Market Assessment

This report provides a detailed market assessment of VP-102 in Common Warts in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

VP-102 Clinical Assessment

The report provides the clinical trials information of VP-102 in Common Warts covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Common Warts is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VP-102 dominance.

• Other emerging products for Common Warts are expected to give tough market competition to VP-102 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VP-102 in Common Warts.
• The in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VP-102 in Common Warts.  

Key Questions Answered

• What is the product type, route of administration and mechanism of action of VP-102?
• What is the clinical trial status of the study related to VP-102 in Common Warts and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VP-102 development?
• What are the key designations that have been granted to VP-102 for Common Warts?
• What is the forecasted market scenario of VP-102 for Common Warts?
• What are the forecasted sales of VP-102 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Common Warts and how are they giving competition to VP-102 for Common Warts?
• Which are the late-stage emerging therapies under development for the treatment of Common Warts?

This product will be delivered within 2 business days.